The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL

Mark R. Wills, A.J. Carmichael, Kim Mynard, +4

Journal of Virology

HistocompatibilityNormal Virus CarrierMultiple Pp65 PeptidesAutoimmune DiseaseCtl Response +13

The Memory Cytotoxic T-Lymphocyte (CTL) Response to Human Cytomegalovirus Infection Contains Individual Peptide-Specific CTL Clones That Have Undergone Extensive Expansion In Vivo

Michael P. Weekes, Mark R. Wills, Kim Mynard, +2

Journal of Virology

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis

Rona Smith, Rachel Jones, Ulrich Specks, +43

Annals of the Rheumatic Diseases

Human Virus-Specific CD8+ CTL Clones Revert from CD45ROhigh to CD45RAhigh In Vivo: CD45RAhighCD8+ T Cells Comprise Both Naive and Memory Cells

Mark R. Wills, Andrew Carmichael, Michael P. Weekes, +4

The Journal of Immunology

Viral ReplicationCd45rohighcd45ra- PopulationNeurovirologyMedicineHuman Retrovirus +11

Human CD28−CD8+ T Cells Contain Greatly Expanded Functional Virus-Specific Memory CTL Clones

Michael P. Weekes, Andrew Carmichael, Mark R. Wills, +2

The Journal of Immunology

Adaptive Immune SystemViral ImmunityImmunologyImmunodominanceCd4 T Cell Responses +15

Large clonal expansions of human virus‐specific memory cytotoxic T lymphocytes within the CD57⁺ CD28^– CD8⁺ T‐cell population

Michael P. Weekes, Mark R. Wills, Kim Mynard, +3

Immunology

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial

Rona Smith, Rachel Jones, Ulrich Specks, +40

Annals of the Rheumatic Diseases

Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas

Dominic McGovern, Mark McClure, Matthew Coates, +8

BMJ Open

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol

Mark McClure, Seerapani Gopaluni, James Wason, +10

Trials